...A. So we had another quarter of strong performance with product revenues growing 25% year-over-year, driven by Jakafi, Opzelura and launches in Europe. B. Jakafi net product revenue grew 14% compared to the second quarter of 2022. C. For Opzelura, the growth trajectory continues with net product revenues in the second quarter of $80 million driven by new patient flow and growth in Refill. D. Additionally, the launch in Europe is underway and Opzelura is now available to patients in Germany and Austria. E. Our other hematology and oncology net product revenues were $64 million for the quarter, up 30% year-over-year, driven by the growth of Pemazyre and Minjuvi in ex U.S. Markets. F. Recently, we announced positive top line results from 2 of our high potential program. G. The TRuE-AD3 study evaluating Ruxolitinib cream in pediatric atopic dermatitis and the AGAVE-201 study evaluating axatilimab in chronic GVHD, met their respective primary endpoint. H. Net product revenues for the quarter...
